These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32683457)

  • 21. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
    Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
    Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
    Tremblay G; Daniele P; Bell T; Chan G; Brown A; Cappelleri JC
    J Comp Eff Res; 2021 May; 10(7):603-612. PubMed ID: 33733815
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
    Schlafer D
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365750
    [No Abstract]   [Full Text] [Related]  

  • 28. Which novel agents hold the greatest promise in AML?
    DiNardo CD
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101106. PubMed ID: 31779980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates on targeted therapies for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
    Venkatakrishnan K; Pickard MD; von Moltke LL
    Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
    He H; Tran P; Gu H; Tedesco V; Zhang J; Lin W; Gatlik E; Klein K; Heimbach T
    Drug Metab Dispos; 2017 May; 45(5):540-555. PubMed ID: 28270565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ivosidenib in acute myeloid leukemia.
    Bruzzese A; Labanca C; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2023; 24(18):2093-2100. PubMed ID: 37874005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
    Maschmeyer G; Bullinger L; Garcia-Vidal C; Herbrecht R; Maertens J; Menna P; Pagano L; Thiebaut-Bertrand A; Calandra T
    Leukemia; 2022 May; 36(5):1215-1226. PubMed ID: 35368047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
    Bohl SR; Bullinger L; Rücker FG
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.
    Menna P; Salvatorelli E; Del Principe MI; Perrone S; Pagano L; Marchesi F; Minotti G
    Chemotherapy; 2021; 66(1-2):47-52. PubMed ID: 33677444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
    McMahon CM; Perl AE
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
    [No Abstract]   [Full Text] [Related]  

  • 40. Glasdegib: First Global Approval.
    Hoy SM
    Drugs; 2019 Feb; 79(2):207-213. PubMed ID: 30666593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.